Prior authorization required — include codes

Prior authorization is required per the plan's coding/claims process; see the policy Codes table for details when submitting requests for PTNS, iTNS, or TTNS.

Authorization for initial 12‑week PTNS and maintenance

Initial PTNS is an initial series of 12 weekly office‑based treatments (30 minutes each in trials); maintenance regimens are individualized (commonly every 4–6 weeks). Prior authorization may be required for device implantation or ongoing maintenance beyond the initial course.

• Initial course: 12 weekly treatments (typical 30‑minute sessions in trials).
• Maintenance: individualized schedule; typical interval every 4–6 weeks; annual physician evaluation recommended.

Prior authorization expected for maintenance PTNS or iTNS

When requesting maintenance PTNS or an implantable tibial nerve stimulator, include documentation of prior treatments tried and response to the initial PTNS course (if applicable); PA is expected for maintenance or implantable device requests.

• Document prior behavioral and pharmacologic therapy failure.
• Document objective evidence of response to initial PTNS for maintenance requests (e.g., GRA at week 13, voiding diary improvements).
• For implants, include device and programming details.

Document prior therapy and rationale for device/therapy eligibility

Authorization for device or therapy eligibility will typically require documentation that conservative therapies failed and rationale aligned with pivotal study entry criteria (e.g., refractory OAB after prior therapies).

• Show prior failed therapies and durations consistent with study criteria (e.g., failed ≥1 second/third‑line therapy or ≥2 OAB medications where specified).
• Provide clinical rationale linking patient to trial populations (non‑neurogenic OAB refractory to prior therapy).

Authorization details for PTNS/TTNS — treatment schedule and prior therapy

Initial PTNS authorization requests should document that the intended treatment is the typical 12 weekly 30‑minute sessions and include evidence of prior conservative therapy failure per policy guidelines.

• Planned schedule: 12 weekly office‑based sessions (30 minutes each as in RCTs).
• Document failure of behavioral therapy (8–12 weeks) and pharmacologic therapy (4–8 weeks).

PA to verify conservative therapy trial and patient selection

Prior authorization is appropriate to verify that conservative therapies were tried and that patient selection aligns with populations supported by evidence (non‑neurogenic OAB who failed behavior and pharmacologic therapy or responded to initial PTNS).

• PA may be used to confirm indication (non‑neurogenic OAB vs neurogenic bladder or fecal incontinence).
• For maintenance PTNS, confirm documented response to initial 12‑week course.

No explicit PA rules in Essential Health Benefits section

The excerpt discusses Essential Health Benefits and state definitions but does not specify explicit prior authorization rules in that section.

Codes listed for PA — inclusion not a coverage guarantee

Codes are listed in the policy for reference, but inclusion of a code does not imply coverage; follow member‑specific benefit plan documentation and include listed codes when applicable in PA submissions.

• Inclusion of a code does not guarantee coverage or reimbursement.
• See the policy Codes table for CPT/Category III and HCPCS codes to include in claims/authorization requests.

Clinical input supports maintenance PTNS — document response for maintenance requests

Clinical input supports maintenance PTNS for responders after an initial course, but the document does not provide an explicit universal PA rule — clinical documentation of response and ongoing efficacy is expected for maintenance requests.

• Clinical respondents endorse maintenance PTNS for non‑neurogenic OAB responders.
• PA practices may vary by plan; submit documentation of prior response and annual physician evaluation for continued efficacy.

Step therapy required — conservative therapies first

PTNS is covered only after an appropriate trial of conservative behavioral therapies (8–12 weeks) and pharmacologic therapy (4–8 weeks) have failed as documented in the medical record.

• Behavioral therapy failure: documented trial of 8–12 weeks without meeting treatment goals.
• Pharmacologic therapy failure: documented trial of 4–8 weeks without meeting treatment goals.

Conservative therapy prerequisite and shared‑decision context

PTNS is intended for individuals who have failed behavioral and pharmacologic therapy or who responded to an initial PTNS course; conservative measures should precede neuromodulation except in shared‑decision contexts.

• Consider shared decision‑making per AUA/SUFU: minimally invasive therapies may be offered without prior trials in some cases.
• Otherwise, conservative therapies are expected before PTNS/iTNS.

Document failed behavioral and pharmacologic therapy before neuromodulation

Before considering PTNS or implantable tibial nerve stimulation, document failed behavioral therapy and pharmacologic therapy and include that documentation with authorization requests.

• Behavioral therapy and pharmacologic therapy should be tried and documented as failed before PTNS/iTNS.
• Include durations of prior trials per policy guidelines.

Stepwise escalation — align patient history with trial populations

Trials enrolled patients refractory to medications or prior therapies; use a stepwise escalation from conservative/medication therapies before implantable tibial neuromodulation and document prior steps.

• Studies generally required prior therapy failure in enrolled populations.
• Provide clear chronology of prior conservative and pharmacologic treatments.

Therapies to try before neuromodulation — list and document conservative care

Before neuromodulation, try conservative therapies such as medical management, pelvic floor retraining, and dietary changes; document these prior interventions in PA requests.

• Conservative comparators include lifestyle modification, pelvic floor exercises, bladder training, and medications.
• Document specific conservative measures attempted and duration.

Conservative therapy prerequisite — include specifics in documentation

Policy context expects behavioral, pelvic floor training, and medications to be used before considering tibial nerve stimulation; include these details in authorization and medical necessity documentation.

• Confirm behavioral and pharmacologic trials were completed per policy durations.
• State reason for moving to PTNS (failed goals or intolerance).

Shared‑decision and guideline context for offering PTNS/iTNS

AUA/SUFU guidance classifies PTNS and implantable tibial nerve stimulation as minimally invasive options after inadequate response or intolerance to behavioral/pharmacologic therapy; document shared‑decision discussions if bypassing stepwise trials.

• If offering minimally invasive therapy without prior trials, document shared‑decision rationale per guideline.
• Reference AUA/SUFU 2024 guidance when applicable.

Maintenance PTNS sequencing — document initial response

Clinical input and policy history note maintenance PTNS after failed behavioral and pharmacologic therapy; ensure PA or documentation for maintenance demonstrates prior response to the initial course.

• Policy history includes consideration of maintenance sequencing.
• Maintenance requests should show initial PTNS response and rationale for ongoing therapy.

Required clinical documentation — prior therapy durations and baseline measures

Documentation must demonstrate failure of behavioral therapy for 8–12 weeks, failure of pharmacologic therapy for 4–8 weeks, and baseline validated symptom measures (e.g., 3‑day voiding diary, OAB‑q SF) when requesting initial PTNS or escalation to implantable therapy.

• Behavioral trial duration: 8–12 weeks.
• Pharmacologic trial duration: 4–8 weeks.
• Baseline measures: OAB‑q SF, 3‑day voiding diary.

Document baseline outcomes and GRA at week 13 for PTNS

Record baseline validated symptom measures and a Global Response Assessment (GRA) at week 13 to document response to the initial PTNS course; include adverse events and maintenance schedule when requesting ongoing treatment.

• Record baseline and 13‑week GRA.
• Include 3‑day voiding diary results and any adverse events.
• Specify maintenance schedule if applicable.

Clinical documentation to support maintenance PTNS medical necessity

For maintenance authorization, document prior 12‑week PTNS course with clinical response (e.g., responder per GRA or ≥50% reduction in UUI episodes) and a plan for maintenance frequency (commonly every 4–6 weeks) plus annual physician follow‑up.

• Evidence of response to initial 12‑week course (GRA or voiding diary showing ≥50% reduction).
• Planned maintenance interval (eg, every 4–6 weeks).
• Annual MD evaluation for continued efficacy.

Suggested supporting documentation for PA requests

Suggested supporting documentation includes prior therapy history (failed ≥1 second‑ or third‑line therapy or failed/intolerant to ≥2 OAB medications), device implanted (for iTNS), objective responder outcomes (voiding diaries, % reduction in UUI episodes), and adverse events and follow‑up duration.

• List prior therapies and durations, including medication trials and prior PTNS or onabotulinumtoxinA if applicable.
• For implants, specify device model (eCoin, Altaviva) and programmed regimen.
• Provide objective outcome measures (voiding diary, percent reduction in UUI episodes).

Required clinical outcome documentation — bowel diaries and validated scales

For outcome measurement in fecal incontinence trials and related coverage requests, document bowel diaries and validated scales (e.g., St. Mark score) at baseline and follow‑up to substantiate clinical response.

• Baseline and post‑treatment 2‑week bowel diaries.
• Validated scores such as St. Mark for fecal incontinence.

Coding and documentation guidance — include policy codes but confirm benefits

Coding and documentation guidance: include relevant CPT/Category III and HCPCS codes from the policy Codes table in submissions and follow member‑specific benefit plan rules; inclusion of a code does not guarantee coverage.

• Use codes listed (eg, 64566, 0587T–0589T, 0816T–0819T, E0736, E0737) as applicable.
• Follow member‑specific benefit plan documentation for coverage determinations.

Suggested documentation elements — initial course and maintenance schedule

Suggested documentation elements: record initial 12‑week weekly PTNS course with clinical response and a maintenance plan of every 4–6 weeks thereafter with yearly MD follow‑up to support ongoing authorization.

• Document initial weekly PTNS x12 and clinical response.
• Document maintenance interval (every 4–6 weeks) and MD yearly follow‑up.

Investigation‑based denial risk — non‑covered indications

Requests for iTNS, TTNS, or PTNS for indications other than non‑neurogenic urinary dysfunction (including neurogenic bladder or fecal incontinence) may be denied as investigational per the policy.

• Implantable and transcutaneous tibial nerve stimulation are considered investigational for many indications per policy statements.
• PTNS for neurogenic bladder and fecal incontinence lacks sufficient evidence and may be denied.

Denial risk — failure to document conservative therapy

Failure to document an initial course of conservative behavioral (8–12 weeks) and pharmacologic (4–8 weeks) therapy prior to PTNS may trigger denial when policy requires prior therapy failure.

• Absence of documented conservative therapy trials per policy durations places requests at risk for denial.
• Ensure chart contains dates, medications, dosages, and outcomes of prior treatments.

Denial risk — missing prior therapy or response documentation

Requests for PTNS or iTNS without documentation of failed behavioral and pharmacologic therapy, or without evidence the patient responded to an initial PTNS course when seeking maintenance or implantation, are at risk for denial.

• For maintenance or implant requests, include objective evidence (GRA, voiding diary) of initial PTNS response.
• Document prior therapy failures and intolerances.

Evidence‑based denial risk — limited comparative evidence and postapproval context

Insufficient randomized controlled trial evidence or absence of sham/active comparator data for implantable devices may lead to denial or requirement for postapproval study data; the eCoin device has an FDA‑required postapproval study.

• Implantable TNS pivotal studies are single‑arm; lack of sham‑controlled RCTs limits certainty.
• FDA required postapproval study for eCoin due to limited preapproval evidence.

Denial risk — no FDA clearance for fecal incontinence

Devices are not FDA cleared for the treatment of fecal incontinence; this regulatory status may affect coverage or authorization decisions.

Denial risk — insufficient evidence for certain indications

Lack of evidence of benefit for neurogenic bladder or fecal incontinence, or absence of documented prior therapy failure and/or response to initial PTNS, may trigger coverage denial.

• RCTs in neurogenic bladder and fecal incontinence generally have not shown PTNS superiority to sham.
• Document indication carefully (non‑neurogenic OAB vs neurogenic bladder vs fecal incontinence).

Denial risk — insufficient comparative evidence for iTNS

Implantable tibial nerve stimulation pivotal studies lack sham‑controlled randomized trials; insufficient comparative evidence may lead to denial when medical necessity is not demonstrated for the specific member context.

• Pivotal iTNS studies were single‑arm with performance goals; no sham‑controlled RCTs yet.
• Ongoing trials and postapproval studies may change evidence base.

Coding inclusion does not guarantee coverage or payment

Inclusion of codes in the policy Codes table does not guarantee member coverage or reimbursement; coverage determinations remain subject to the member's benefit plan documentation and the written medical policy.

Denial risk not explicitly specified for maintenance PTNS

Clinical input supports maintenance PTNS in responders, but the excerpt does not specify explicit PA or denial triggers for maintenance beyond usual documentation expectations.

• Clinical respondents endorse maintenance after initial response.
• No explicit PA rule for maintenance is stated in these chunks; follow plan PA processes.